About Us About Us

Board of Directors

Ann MacDougall

Ann MacDougall

Interim Chair of the Board

Ann MacDougall joined our Board November 2019. Ms. MacDougall is an experienced executive, attorney and impact investor and co-founded the Dunollie Fund, where she is CEO. Until recently she was President of Encore.org, a national organization building a movement for individuals developing second careers in public or non-profit service. She has also been Chief Operating Officer of Acumen, a global investment fund focused on goods and services for low-income customers. She had a long legal career at PriceWaterhouseCoopers, including as General Counsel/Management Committee Member of the U.S. firm and Global Deputy General Counsel based in Paris. Ms MacDougall sits on the board of Opiant Pharmaceuticals,Inc where she chairs the Compensation Committee and is a member of the Governance and Nominations Committee. She earned her BA at Tufts University, her JD at Brooklyn Law School and was a fellow at the Harvard Advanced Leadership Initiative.


Gerard Ber

Gérard Ber, Ph.D.


Dr. Gérard Ber joined our Board November 2019. Dr. Ber has more than 30 years of experience in molecular nuclear medicine. In 2002, Dr. Ber co-founded Advanced Accelerator Applications S.A. (“AAA”), and was its Chief Operating Officer from 2002 to 2018, when it was sold to Novartis AG for nearly $4 billion. Dr. Ber grew AAA from a start-up to a global leader in nuclear medicine and was member of its board of directors from 2002 to 2014, when AAA listed on The Nasdaq Global Select Market. Mr. Ber was responsible for all aspects of US and Worldwide commercial efforts, drug development, supply chain, and business development activities at AAA, including the successful launch of Lutathera® for the treatment of gastropancreatic neuroendocrine tumors and various diagnostic radiopharmaceutical agents . Prior to joining AAA, Mr. Ber served as the Director of OM Pharma’s Western European group from 2000 to 2002, the Director General and Director of Marketing and Commerce for CIS Medipro from 1994 to 2000, and in various management roles at CIS Bio International from 1984 to 1994. Mr. Ber serves as a Board member of Y-mAbs, a NASDAQ-listed late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. He received his PhD degree in Pharmacy from the Scientific and Medical University of Grenoble and a degree in marketing and international commerce from the Institut de Pharmacie Industrielle de Paris in Paris, France.


Bradley Campbell

Bradley L. Campbell, M.B.A.


Mr. Campbell joined the Board in 2016. He is the President and Chief Operating Officer of Amicus Therapeutics Inc, a biotechnology company focused on developing and commercializing next generation therapies for rare diseases. Mr Campbell is also a Board Member of Amicus as well as the Alliance for Regenerative Medicine (ARM). He brings nearly two decades of experience in the orphan drug industry. Prior to Amicus, Mr. Campbell held positions of increasing responsibility at Genzyme and Bristol-Myers Squibb and as financial strategy consultant for Marakon Associates. He is also past President of the National Tay-Sach and Allied Diseases Association Board of Directors and currently services on their Corporate Advisory Council. Mr. Campbell received a B.A. in Public Policy from Duke University and an M.B.A. from Harvard Business School.


Eric J. Ende

Eric J. Ende, M.D., M.B.A.


Dr. Eric Ende joined our Board November 2019. Since 2009, Dr. Ende has served as President of Ende BioMedical Consulting Group. Ende BioMed is focused on helping life sciences companies raise capital, identify licensing partners and acquirers, and optimizing corporate structure. In addition, it analyzes both private and public investment opportunities for clients within the life sciences industry. Ende also helps activist investors gain seats on Company Boards.

Dr. Ende was a Director on Genzyme’s Board from 2010 – 2011 until it was acquired by Sanofi-Aventis for $21 B in 2011. During his tenure on Genzyme’s Board, he was a member of the Audit and Risk Management Committees. Ende is currently on the Board of Directors of Matinas BioPharma, where he is the Chairman of the Compensation Committee and is serving on the Audit as well as the Nomination & Governance committees. Ende is also on the Board of Directors of Avadel plc, where he is the Chairman of the Nomination & Corporate Governance Committee and is serving on the Audit & Compensation committees. Ende is also on the Technology Transfer Committee of Mount Sinai Innovation Partners. He also served as the Chairman of the Unsecured Creditor’s Committee overseeing the Egenix Bankruptcy and on the subsequent Liquidating Trust Committee.

From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch. From 2000 – 2002, Ende was the senior biotechnology analyst at Banc of America Securities. And, from 1997 – 2000, he was a biotechnology analyst at Lehman Brothers. During Dr. Ende’s career as a biotechnology analyst, he was named to Institutional Investor’s All-America Equity Research Team six times as well as to The Greenwich Survey list of top analysts. He was also named Top Stock Picker by The Street.com and Best Earnings Estimator by Forbes.com.

Dr. Ende received an MBA in Finance & Accounting from NYU – Stern Business School in 1997, an MD from Mount Sinai School of Medicine in 1994, and a BS in Biology and Psychology from Emory University in 1990.


Karen Ferrante

Karen Jean Ferrante, M.D.


Dr. Ferrante joined our Board in January 2014. She was most recently head of Research and Development and Chief Medical Officer of Tokai Pharmaceuticals, Inc., which was a publicly traded biopharmaceutical company developing treatments for prostate cancer and other hormonally driven diseases. From September 2007 to July 2013, Dr. Ferrante held senior positions at Millennium Pharmaceuticals and its parent company, Takeda Pharmaceuticals, most recently as Oncology Therapeutic Area and Cambridge USA Site Head. From 1999 to 2007, she held positions of increasing responsibility at Pfizer Global Research & Development, culminating as Vice President, Oncology Department. She began her career in the pharmaceutical industry in 1995 as Associate Director of Clinical Oncology at Bristol-Myers Squibb Company. Prior to that, she was at the New England Deaconess Hospital in Boston (Beth Israel Deaconess), where she completed her internship and residency in internal medicine followed by her fellowship in hematology and oncology. While at the Beth Israel Deaconess Hospital, she served as Instructor, Clinical Instructor and Clinical Fellow in Medicine at the Harvard Medical School, and previously was a Bacteriologist for the City of Providence, Rhode Island Water Supply Board. Dr. Ferrante holds a B.S. in Chemistry and Biology from Providence College and an M.D. from Georgetown University.


Heinz Mausli

Heinz Mäusli, M.B.A.


Heinz Mäusli joined our Board in November 2019. He serves on the Board of Directors of Inventiva, a clinical-stage biopharmaceutical company, listed on Euronext Paris. Mr. Mäusli brings over 15 years of experience in molecular nuclear medicine to Progenics. He was one of the senior executives who built Advanced Accelerator Applications (AAA) from a start up to a global leader in this field. He served as AAA’s Chief Financial Officer from 2003 until July 2018. He also was the company’s general counsel from 2003 to 2015 and a member of its Board of Directors from 2008 to 2014. Prior to AAA, he was a management consultant. Mr. Mäusli received a lic.oec. from University of St.Gallen in Switzerland and an M.B.A. from Columbia Business School.


David Mims

David W. Mims


David W. Mims joined our Board in November 2019. Mr. Mims has served as a member of the board of directors at each of Guideway Care, a healthcare company that provides technology-enabled care guidance, since May 2017 and SouthPoint Bank, a community banking institution, since August 2015. Previously, Mr. Mims served as President, U.S. Specialty Pharmaceuticals for Aptalis Pharma Inc. (“Aptalis”) (f/k/a Axcan Pharma Inc.), a privately held pharmaceutical company, from May 2011 until May 2014, shortly after it was acquired by Forest Laboratories, Inc. (formerly NYSE: FRX). While at Aptalis, Mr. Mims managed over 200 employees and grew the business to over $475 million in annual net sales. Mr. Mims similarly served as President, U.S. Specialty Pharmaceuticals at Axcan Intermediate Holdings Inc., the parent company of Axcan Pharma Inc. (formerly TSE: AXP and NASDAQ: AXCA), from February 2008 until May 2014 and as a member on its board from 2000 to 2007. Mr. Mims began working at Axcan Pharma Inc. as Executive Vice President and Chief Operating Officer in 2000 after the company acquired Scandipharm, Inc., a privately held pharmaceutical company, which Mr. Mims helped found and for which he served as Vice President, Chief Operating Officer and Chief Financial Officer, from 1991 until 1998. During his career as a pharmaceutical executive, Mr. Mims has played a significant role in raising over $1 billion in capital and successfully leading multiple commercial organizations including the new product launches. Mr. Mims was also an integral part of multiple transactions, including the sale of Scandipharm to Axcan Pharma, Inc. for ~$100 million, the sale of Axcan Pharma, Inc. to TPG Capital for $1.3 billion, the acquisition of Eurand, Inc. for $583 million and the sale of Aptalis to Forest Laboratories for $2.9 billion. Currently, Mr. Mims serves as a member of the American Institute of Certified Public Accountants and Alabama Society of Certified Public Accountants. Previously, Mr. Mims served as a director of the University of Alabama at Birmingham Research Foundation. Mr. Mims is a licensed CPA (inactive). Mr. Mims received his B.S. in accounting from Auburn University.